News stories about Teladoc (NYSE:TDOC) have been trending somewhat positive recently, Accern Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Teladoc earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned media stories about the health services provider an impact score of 46.2123381718648 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the news articles that may have impacted Accern’s scoring:
- 2 Stocks to Track: Teladoc, Inc. (NYSE:TDOC), AxoGen, Inc. (NASDAQ:AXGN) – The Oracle Examiner (oracleexaminer.com)
- The story behind the curtains – Sears Holdings Corporation (SHLD … – NMSU Nеws (nmsunews.com)
- Where to look at selling opportunities on Teladoc, Inc. (TDOC) – Wall Street Morning (wallstreetmorning.com)
- Teladoc, Inc. (TDOC) to reach EPS growth of -20.70% for this year – Wallstreet Investorplace (wallstreetinvestorplace.com)
- Teladoc, Inc. (TDOC) Stock Swings Under Technical Examination – Investing News Update (investingbizz.com)
Teladoc stock opened at $43.10 on Thursday. Teladoc has a 1-year low of $22.73 and a 1-year high of $44.65. The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.37. The firm has a market capitalization of $2,564.73, a PE ratio of -22.80 and a beta of 0.36.
Several equities analysts have recently issued reports on the company. KeyCorp restated an “overweight” rating and set a $50.00 target price (up from $41.00) on shares of Teladoc in a research report on Thursday, March 15th. Deutsche Bank lowered Teladoc from a “buy” rating to a “hold” rating and set a $45.00 target price for the company. in a research report on Thursday, March 15th. Canaccord Genuity boosted their target price on Teladoc from $43.00 to $45.00 and gave the stock a “buy” rating in a research report on Wednesday, February 28th. Chardan Capital restated a “buy” rating and set a $47.00 target price (down from $48.00) on shares of Teladoc in a research report on Wednesday, February 28th. Finally, Cantor Fitzgerald restated a “hold” rating and set a $35.00 target price (up from $31.00) on shares of Teladoc in a research report on Tuesday, February 27th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and eleven have assigned a buy rating to the company. Teladoc presently has an average rating of “Buy” and a consensus price target of $41.36.
In other news, President Peter A. Mcclennen sold 27,533 shares of Teladoc stock in a transaction dated Wednesday, March 7th. The stock was sold at an average price of $43.01, for a total transaction of $1,184,194.33. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Andrew Turitz sold 36,210 shares of Teladoc stock in a transaction dated Tuesday, March 6th. The shares were sold at an average price of $40.39, for a total value of $1,462,521.90. Following the transaction, the senior vice president now owns 16,700 shares in the company, valued at approximately $674,513. The disclosure for this sale can be found here. Insiders have sold a total of 364,494 shares of company stock worth $14,665,947 in the last quarter. 4.47% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION WARNING: This article was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://ledgergazette.com/2018/03/22/teladoc-tdoc-earns-media-sentiment-score-of-0-16.html.
Teladoc Company Profile
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.